Recent developments highlight Mangoceuticals' expansion into new markets, research advancements, and a significant merger transaction.

• Mangoceuticals announced a merger with Nuclea Energy to advance nuclear microreactor technology, with the transaction subject to multiple closing conditions including shareholder and regulatory approvals [N1].
• The company expanded its patent portfolio in nutraceuticals through acquisitions [N2].
• Field studies of MGX-0024 for poultry respiratory diseases reported 100% survival rates [N3].
• Mangoceuticals entered the wellness pouch market and appointed Tim Corkum to lead the new unit [N4].
• The company acquired intellectual property assets from Smokeless Technology Corp. to expand into the oral pouch delivery market [N5].
• Mangoceuticals secured exclusive rights for the plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada [N6].
• Launched PeachesRx, a women's telehealth brand for wellness and GLP-1 treatments [N7].
• Advanced research on respiratory illness prevention technologies targeting avian influenza [N8].

Mangoceuticals has demonstrated capability in acquiring intellectual property and exclusive rights in nutraceuticals, expanding into new wellness markets, and advancing research in areas such as poultry respiratory diseases and antiviral prevention. The pending merger with Nuclea Energy could diversify its business into nuclear microreactor technology, potentially broadening its market and technological base. Strategic partnerships and service agreements with related parties support its operational capabilities.

The company faces significant regulatory risks related to its reliance on a related-party compounding pharmacy and telehealth prescribing models, which are under increased FDA scrutiny. Financially, it reports net losses and limited liquidity, with challenges in maintaining Nasdaq listing compliance due to low stock price and equity levels. The complex merger transaction with Nuclea Energy involves substantial dilution and uncertain completion, which could disrupt operations and shareholder value. Failure to comply with listing requirements could lead to delisting and reduced market liquidity.

Mangoceuticals' moat is based on its proprietary pharmaceutical and nutraceutical product portfolio, exclusive rights to certain plant-based nutriceuticals, and its related-party pharmacy arrangements that enable compounding under Section 503A. Its expansion into telehealth and wellness markets, along with ongoing research in antiviral and respiratory illness prevention, provide potential differentiation. However, the company faces regulatory risks due to the nature of its compounding and telehealth business model and has limited financial resources, which may constrain its ability to scale or defend its market position.

• Nasdaq Listing Compliance Risk: Mangoceuticals is not currently in compliance with Nasdaq's minimum bid price requirement and other listing standards, with deadlines for regaining compliance extended to February 1, 2027. Failure to comply may result in delisting, adversely affecting liquidity and investor access.
• Regulatory Risk Related to Pharmacy Compounding and Telehealth: The company's reliance on a related-party pharmacy operating under Section 503A exposes it to regulatory scrutiny. FDA concerns about compounding at scale, telehealth prescribing practices, and marketing could lead to enforcement actions, increased compliance costs, or restrictions on product offerings.
• Merger Transaction Risks: The pending merger with Nuclea Energy is subject to multiple closing conditions including shareholder and regulatory approvals. The transaction structure is complex, involves significant dilution to existing shareholders, and may face delays or termination, which could disrupt business and negatively impact stock price.
• Financial and Liquidity Risks: Mangoceuticals reported a net loss of $1.3 million and limited liquidity with a current ratio of 0.18 as of June 30, 2026. These financial constraints may limit operational flexibility and ability to invest in growth or regulatory compliance.

• Mangoceuticals, Inc. operates in pharmaceutical and nutraceutical sectors with activities including research, development, and marketing of pharmaceutical and over-the-counter products [S1].
• The company has a Master Services Agreement and Consulting Agreements with Epiq Scripts, a related party pharmacy, for pharmacy services and consulting related to product development and global expansion [S1].
• Epiq Scripts provides pharmacy consulting and services under agreements that include fees based on prescription drug sales and rights of first negotiation and refusal for certain pharmaceutical services [S1].
• Mangoceuticals has a wholly-owned subsidiary, Mango & Peaches, which holds assets including MangoRx Mexico and MangoRx UK, and assumed liabilities related to these assets [S1].
• The company has entered into various service agreements with Greentree Financial Group for bookkeeping, financial reporting, and compliance services [S1].
• Mangoceuticals has reported financial figures for the quarter ended June 30, 2026: revenue of $68,757, net loss of $1,312,653, basic and diluted EPS of -$0.09, cash and equivalents of $228,688, current assets of $245,687, and current liabilities of $1,398,063 [S2].
• Liquidity ratios as of June 30, 2026, include a current ratio of 0.18 and a cash ratio of 0.16, indicating limited short-term liquidity [S2].
• The company is not currently in compliance with Nasdaq's minimum bid price requirement of $1.00 per share and has received notices from Nasdaq regarding this non-compliance, with compliance deadlines extended to February 1, 2027 [S2].
• Mangoceuticals effected a 1-for-15 reverse stock split in October 2024 to address Nasdaq listing requirements, with restrictions on further reverse splits before October 2026 [S2].
• The company depends on a related-party pharmacy operating under Section 503A of the FFD&C Act for compounding certain products, which exposes it to regulatory risks due to increased FDA scrutiny of compounding pharmacies and telehealth prescribing models [S2].
• Mangoceuticals has advanced research and development in areas including antiviral research for avian flu prevention, respiratory illness prevention technologies, and poultry respiratory disease treatments [N3][N8].
• The company has expanded into the wellness pouch market and acquired intellectual property assets to support oral pouch delivery products [N4][N5].
• Mangoceuticals secured exclusive rights for a plant-based nutriceutical, Diabetinol®, targeting pre-diabetes and weight management markets in the U.S. and Canada [N6].
• The company launched PeachesRx, a women's telehealth brand focused on wellness and GLP-1 treatments [N7].
• Mangoceuticals has signed exclusive distribution agreements for its Dermytol® skincare line [N8].
• The company announced a merger with Nuclea Energy to advance nuclear microreactor technology, with the transaction subject to multiple closing conditions including shareholder and regulatory approvals [N1].
• The merger is structured in two stages: an initial Closing followed by Completion, with complex exchangeable share structures and significant dilution expected for existing shareholders [N1].
• The company faces risks related to potential delisting from Nasdaq, regulatory scrutiny of its pharmacy compounding and telehealth business model, and uncertainties around the completion of the merger transaction [S2][N1].